Abstract 3989
Background
The AVANT study, with a median follow-up (FU) of 4 years, did not improve disease-free survival (DFS; the primary endpoint) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III resected colon cancer (de Gramont A, Lancet Oncol, 2012). We report here long-term results with 10-year maximum FU.
Methods
OS and DFS calculation was done by the Kaplan-Meier method and Cox regression model. Cause of death distribution was evaluated with the chi-square test.
Results
2867 patients had stage III colon cancer (arm A: FOLFOX4, n = 955; arm B: FOLFOX4-bevacizumab, n = 960; arm C: XELOX-bevacizumab, n = 952). With a median FU of 6.73 years (5.51-10.54), 672 patients died, of whom 198 (20.7%) in arm A, 250 (26.0%) in arm B, and 224 (23.5%) in arm C. The 3-year DFS rates were 76.9%, 73.7%, and 75.2% in arms A, B, and C, respectively and the 5-year OS rates were 84.7%, 80.8%, and 81.7%, (DFS P = 0.1743 and OS P = 0.0294). The OS hazard ratio was 1.29 (95% CI 1.07-1.55; P = 0.008) for arm B vs arm A and 1.15 (95% CI 0.95-1.39; P = 0.1474) for arm C vs arm A. The DFS hazard ratio was 1.16 (95% CI 0.99-1.37; P = 0.0626) for arm B vs arm A and 1.1 (95% CI 0.93-1.29; P = 0.2690) for arm C vs arm A. Colon cancer-related deaths occurred in 542 among 672 dead patients (80.7%); arm A: 157/198 (79.3%); arm B: 205/250 (82.0%), arm C:180/224 (80.4%), with no difference between arms (P = 0.7641). Non-colon cancer-related deaths occurred in 130 patients: arm A: 41 (20.7%); arm B: 45 (18.0%), arm C: 44 (19.6%). The 8-year OS rate in patients alive without relapse at 4 years was 95.2%, 94.7%, and 95.4% in arm A, B, and C respectively. Deaths related to cardiovascular diseases and sudden deaths were reported in 13 (6.6%), 17 (6.8%), and 14 (6.3%) patients, in arm A, B, and C respectively. In Cox analysis, gender, age, histological grade, performance status, and T and N stage were independent prognostic factors for DFS in stage III.
Conclusions
Updated result of the AVANT study is consistent with the primary reported data concerning DFS, with a potential detrimental effect of the addition of bevacizumab to oxaliplatin-based adjuvant therapy on OS, in patients with stage III colon cancer, without increase in non-colon cancer-related deaths.
Clinical trial identification
NCT00112918.
Editorial acknowledgement
Magdalena Benetkiewicz (GERCOR).
Legal entity responsible for the study
Hoffmann-La Roche.
Funding
Roche.
Disclosure
T. André: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD Oncology; Honoraria (self), Travel / Accommodation / Expenses: Roche/Ventana; Honoraria (self): Sanofi; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self): Chugai; Honoraria (self): Yakult; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: HalioDx. D. Vernerey: Advisory / Consultancy: HalioDx; Honoraria (self), Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy: OSE Immunotherapeutics; Advisory / Consultancy: Prestizia; Honoraria (self): Celgene. G.M. Bodoky: Advisory / Consultancy: Bayer; Advisory / Consultancy: Ipsen; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche. F. Rivera: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Merck Serono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Lilly; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Celgen; Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self): Tecnofarma. R. Geva: Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Travel / Accommodation / Expenses: BMS; Honoraria (self): Lilly; Honoraria (self): Medison; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): Janssen; Honoraria (self): Takeda; Honoraria (institution), Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: GAD Medical; Research grant / Funding (institution), Educational grant to the research unit - Novartis: Novartis. P. Österlund: Honoraria (self), Research grant / Funding (institution), Travel /Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation /Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Nordic Drugs; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Baxalta/Servier; Honoraria (self), Speaker Bureau / Expert testimony: Eisai; Travel / Accommodation / Expenses: AbbVie; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Pierre Fabre. E. Van Cutsem: Advisory / Consultancy, Research grant / Funding (self): Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Bayer; Honoraria (self): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Servier; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Research grant / Funding (self): MSD; Advisory / Consultancy, Research grant / Funding (self): Ipsen; Advisory / Consultancy, Research grant / Funding (self): Sanofi; Advisory / Consultancy, Research grant / Funding (self): Boehringer. D. Cunningham: Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Medimmune; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Merrimack; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Roche. J. Tabernero: Honoraria (self), Advisory / Consultancy: Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsenm Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partn; Research grant / Funding (institution): Agendia BV, Amgen SA, Debiopharm International SA, Janssen-Cilag SA, Mologen AGm Novartis Farmacéutica SA, Pharma Mar, Roche Farma SA, Laboratorios Servier SL, Symphogen A/S; Honoraria (self), Leadership role: American Society of Clinical Oncology - ASCO. American Association for Cancer Research - AACR. European Organization for Research and Treatment of Cancer - EORTC. Cancer Core Europe (CCE). Worldwide Innovative Networking (WIN) Consortium in Personalized C; Leadership role, Non-remunerated activity/ies: Institute for Biomedical Research (IRB) Bellinzona (2013). IRCC Candiolo Cancer Institute (2013-2017). University Medical Centre Utrecht (UMC Utrecht) (2014). Cambridge Cancer Centre (2014). Institut Gustave Roussy (2015). German Consortium for Translation. A. De Gramont: Honoraria (self): Yakult; Honoraria (self): Chugai Pharma. All other authors have declared no conflicts of interest.
Resources from the same session
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract
5792 - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Chanwoo Kim
Session: Poster Display session 2
Resources:
Abstract
3728 - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer
Presenter: Besma Graja
Session: Poster Display session 2
Resources:
Abstract
3395 - Re-sentinel node biopsy for local recurrence after breast-conserving surgery
Presenter: Yuka Matsubara
Session: Poster Display session 2
Resources:
Abstract
4302 - Assessment of prognostic and therapeutic factors in men with breast cancer
Presenter: Daniel Herrero Rivera
Session: Poster Display session 2
Resources:
Abstract
4263 - Genomic Profiling of Chinese Breast Cancer Patients
Presenter: Zhonghua Tao
Session: Poster Display session 2
Resources:
Abstract
2406 - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Presenter: Naomi Walsh
Session: Poster Display session 2
Resources:
Abstract
2575 - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations
Presenter: Nicholas C. Turner
Session: Poster Display session 2
Resources:
Abstract
4499 - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors
Presenter: Evgeny Imyanitov
Session: Poster Display session 2
Resources:
Abstract
4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience
Presenter: Sercan Aksoy
Session: Poster Display session 2
Resources:
Abstract